The first patient has entered a clinical trial initiated by Oncology Ventures testing the company’s cancer drug for treating Multiple Myeloma (MM).
This marks the entry into the territory of shooting star Genmab, who is expected to reach billion dollar sales of its MM drug Darzalex.
The drug candidate, an immuno-cancer therapy named APO010, is the second potential drug by Oncology Venture. In the hopes of identifying the patients who will benefit from treatment with APO010 the company will apply the DRP (Drug Response Predictor) technology to screen patients.
Oncology Venture has a license to use seven DRPs developed by Danish diagnostics company Medical Prognosis Institute. More than 50 patients have already consented to have their tumor tissue DRP analyzed. A total of 150 patients will be screened using a DRP.